Mostrando 3 resultados de: 3
Filtros aplicados
Bisphosphonates or denosumab discontinuation and risk of fractures: Response to the Letter by Anastasilakis et al.
OtherAbstract:Palabras claves:Autores:Anagnostis P., Ceausu I., Depypere H., Faustino R. Pérez-López, Goulis D.G., Lambrinoudaki I., Mintziori G., Mueck A., Paschou S.A., Rees M., Senturk L.M., Simoncini T., Stevenson J.C., Stute P., Trémollieres F.A.Fuentes:scopusDrug holidays from bisphosphonates and denosumab in postmenopausal osteoporosis: EMAS position statement
ReviewAbstract: Background Bisphosphonates and denosumab are used extensively in the treatment of postmenopausal ostPalabras claves:Alendronate, Bisphosphonates, Denosumab, Drug holiday, Risedronate, Zoledronic acidAutores:Anagnostis P., Ceausu I., Depypere H., Faustino R. Pérez-López, Goulis D.G., Lambrinoudaki I., Mintziori G., Mueck A., Paschou S.A., Rees M., Senturk L.M., Simoncini T., Stevenson J.C., Stute P., Trémollieres F.A.Fuentes:scopusNutritional guidelines for the management of insulin resistance
ReviewAbstract: Obesity and its related co-morbidities, namely type 2 diabetes (T2D), pose a significant global publPalabras claves:Guidelines, Insulin Resistance, nutrition management, obesity, Polycystic ovary syndrome, Type 2 DiabetesAutores:Barrea L., Caprio M., Ceriani F., Chavez A.O., Colao A., El Ghoch M., Frias Toral Evelyn, Mehta R.J., Mendez V., MUScogiUri G., Paschou S.A., Pazderska A., SaVaSTaNo S.Fuentes:googlescopus